Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition

Authors:

Abstract
The transition from benign to malignant growth is a pivotal yet poorly understood step in cancer progression that marks the shift from a pathologically inert condition to a clinically lethal disease. Here, we integrate lineage tracing, single-cell and spatial transcriptomics to visualize the molecular, cellular and tissue-level events that promote or restrain malignancy during the tumor initiation in mouse models of pancreatic ductal adenocarcinoma (PDAC). We identify a discrete progenitor-like population of KRAS-mutant cells that co-activates oncogenic and tumor-suppressive programs—including p53, CDKN2A, and SMAD4—engaging senescence-like responses and remodeling their microenvironment, ultimately assembling a niche that mirrors invasive PDAC. KRAS inhibition depletes progenitor-like cells and dismantles their niche. Conversely, p53 suppression enables progenitor cell expansion, epithelial–mesenchymal reprogramming, and immune-privileged niche formation. These findings position the progenitor-like state as the convergence point of cancer-driving mutations, plasticity, and tissue remodeling—revealing a critical window for intercepting malignancy at its origin.
All Related Versions
Funding Information
  • The Center for Experimental Immuno-Oncology Scholars Program, MSKCC
  • Rackham International Student Fellowship, University of Michigan
  • Geoffrey Beene Cancer Research Center Grant, MSKCC
  • Instituto Ramón y Cajal de Investigación Sanitaria (RYC2023-045857- I)
  • AECC 2022 Excellence Program (EPAEC222649IRB)
  • Spanish National Research Agency (PID2024-159806OB-I00)
  • Spanish National Research Agency (TRANSCAN2022-784-028)
  • Spanish National Research Agency (TRNSC235656ALON project)
  • Cycle for Survival
  • European Research Council (ERC Consolidator Grant IGNITE (Grant Agreement: 101171929))

This publication has 159 references indexed in Scilit: